Prilenia Shares Preliminary Topline Results from Phase 3 PROOF-HD Clinical Trial in Huntington’s Disease and Data from Phase 2 HEALEY ALS Platform Trial of Pridopidine at the 75th American Academy of Neurology (AAN) Annual Meeting
Retrieved on:
Tuesday, April 25, 2023
Health, Neurology, Clinical Trials, Research, Science, Biotechnology, CHDI, SWR, HSG, Patient, Disease, Regimen, Therapy, Clinical trial, TMS, Expanded access, NYU, Hope, TFC, HIV disease progression rates, Hospital, FDA, Massachusetts General Hospital, European Lead Factory, Conference, Safety, Cognition, New York University Grossman School of Medicine, Department of Neurology, Xuanwu hospital, GHI, DSM-IV codes, Master of Science, Functional, HD, Speech, AAN, Respiration, Quality of life, American Academy, Trial of the century, Harvard Medical School, Annual general meeting, Periodic breathing, Pharmaceutical industry, Medical imaging, ALS, Huntington's disease
These initial results, along with recently announced findings from the pridopidine arm of the HEALEY ALS Platform Trial, were presented today at the 75th American Academy of Neurology (AAN) Annual Meeting taking place in Boston, MA.
Key Points:
- These initial results, along with recently announced findings from the pridopidine arm of the HEALEY ALS Platform Trial, were presented today at the 75th American Academy of Neurology (AAN) Annual Meeting taking place in Boston, MA.
- Effects on both of these measures were reduced by the use of concomitant medications.
- Pridopidine was well-tolerated with no serious treatment-related adverse events, with a safety and tolerability profile similar to placebo and consistent with previous clinical studies.
- “The Company is committed to advancing pridopidine in both HD and ALS, as well as additional indications.”